NEW YORK (GenomeWeb News) – Months removed from the commercial launch of its first test, Theranostics Health is targeting reimbursements as it looks to build a revenue stream for the test.

The Rockville, Md.-based firm launched the TheraLink HER Family Assay at the American Society of Clinical Oncology annual meeting in June, marking the next chapter in Theranostics' commercial build-out.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.